⦿ Executive Snapshot

• What: MannKind stock surged by +39.28% following the announcement of a new ralinepag dry powder inhalation (DPI) development program in partnership with United Therapeutics Corporation.
• Who: MannKind Corporation and United Therapeutics Corporation.
• Why it matters: This partnership potentially unlocks significant financial milestones for MannKind, reflecting investor confidence in the commercial viability of their new drug formulation amidst a positive market backdrop.

⦿ Key Developments

• MannKind announced it is developing a dry powder inhalation formulation of ralinepag, known as MNKD-1501, for United Therapeutics under an expanded collaboration agreement.
• MannKind is eligible to receive up to $35 million in development milestones plus 10% royalties on net sales from the ralinepag DPI program.
• The original 2018 agreement with United Therapeutics led to the successful development and FDA approval of Tyvaso DPI, which generated $1.3 billion in revenue in 2025.
• The announcement comes after United Therapeutics reported that its Phase 3 ADVANCE OUTCOMES study met its primary endpoint, enhancing the credibility of the new DPI program.
• Prior analyst coverage was mixed, with H.C. Wainwright lowering its price target on MannKind from $11 to $8 while maintaining a Buy rating.

⦿ Strategic Context

• The partnership with United Therapeutics reframes MannKind's relationship as expansive, moving past previous challenges such as the introduction of TreSMI, which had negatively impacted MannKind's stock.
• Historically, MannKind has relied on partnerships to drive innovation and market presence, with the ralinepag DPI program seen as a pivotal step in their growth trajectory.

⦿ Strategic Implications

• Immediate market consequences include a significant stock price increase due to renewed investor confidence in MannKind's product pipeline and financial outlook.
• Long-term implications could see MannKind positioning itself as a key player in the pulmonary arterial hypertension market, potentially increasing its market share and revenue streams.

⦿ Risks & Constraints

• Potential regulatory hurdles concerning the approval and commercialization of the new DPI formulation could impact timelines and financial projections.
• Increased competition from other inhalation therapies, particularly those introduced by United Therapeutics, may pose challenges to MannKind’s market positioning.

⦿ Watchlist / Forward Signals

• Upcoming milestones include the potential financial results report from MannKind on May 6, 2026, which could further influence investor sentiment.
• Future developments in regulatory approvals for MNKD-1501 and market performance of Tyvaso DPI will be critical indicators of success or failure for MannKind's strategy.